LIDOCAINE

Lidocaine Adverse Events Reported to the FDA Over Time

How are Lidocaine adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Lidocaine, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Lidocaine is flagged as the suspect drug causing the adverse event.

Most Common Lidocaine Adverse Events Reported to the FDA

What are the most common Lidocaine adverse events reported to the FDA?

Convulsion	288 (1.61%)
Cardiac Arrest	210 (1.17%)
Dizziness	203 (1.13%)
Anaphylactic Shock	190 (1.06%)
Loss Of Consciousness	190 (1.06%)
Drug Toxicity	184 (1.03%)
Drug Ineffective	167 (.93%)
Dyspnoea	165 (.92%)
Hypotension	164 (.92%)
Overdose	159 (.89%)
Anaesthetic Complication	150 (.84%)
	Show More
Blood Pressure Decreased	147 (.82%)
Tachycardia	142 (.79%)
Nausea	136 (.76%)
Blood Pressure Increased	135 (.75%)
Drug Interaction	133 (.74%)
Pain	128 (.71%)
Medication Error	124 (.69%)
Shock	120 (.67%)
Bradycardia	119 (.66%)
Hypoaesthesia	113 (.63%)
Headache	105 (.59%)
Anaphylactic Reaction	101 (.56%)
Incorrect Route Of Drug Administrat...	91 (.51%)
Respiratory Arrest	91 (.51%)
Drug Hypersensitivity	88 (.49%)
Methaemoglobinaemia	88 (.49%)
Erythema	87 (.49%)
Grand Mal Convulsion	86 (.48%)
Confusional State	84 (.47%)
Hypertension	84 (.47%)
Post Procedural Complication	82 (.46%)
Vomiting	82 (.46%)
Ventricular Tachycardia	81 (.45%)
Septic Arthritis Staphylococcal	80 (.45%)
Cyanosis	79 (.44%)
Oxygen Saturation Decreased	79 (.44%)
Agitation	78 (.44%)
Heart Rate Increased	78 (.44%)
Malaise	78 (.44%)
Pyrexia	77 (.43%)
Depressed Level Of Consciousness	74 (.41%)
Syncope	74 (.41%)
Tremor	74 (.41%)
Ventricular Fibrillation	74 (.41%)
Bronchospasm	73 (.41%)
Coma	73 (.41%)
Somnolence	73 (.41%)
Angioedema	71 (.4%)
Hypersensitivity	71 (.4%)
Off Label Use	71 (.4%)
Palpitations	70 (.39%)
Urticaria	70 (.39%)
Anxiety	68 (.38%)
Cardio-respiratory Arrest	67 (.37%)
Hyperhidrosis	66 (.37%)
Procedural Complication	66 (.37%)
Drug Exposure During Pregnancy	65 (.36%)
Wrong Technique In Drug Usage Proce...	65 (.36%)
Pallor	64 (.36%)
Toxic Anterior Segment Syndrome	64 (.36%)
Asthenia	63 (.35%)
Oedema Peripheral	63 (.35%)
Musculoskeletal Pain	62 (.35%)
Heart Rate Decreased	58 (.32%)
Pain In Extremity	57 (.32%)
Paraesthesia	56 (.31%)
Visual Acuity Reduced	56 (.31%)
Fatigue	54 (.3%)
Injection Site Pain	52 (.29%)
Weight Decreased	52 (.29%)
Death	51 (.28%)
Rash	51 (.28%)
Feeling Abnormal	50 (.28%)
Hypertensive Crisis	50 (.28%)
Vision Blurred	50 (.28%)
Burning Sensation	49 (.27%)
Insomnia	49 (.27%)
Pruritus	49 (.27%)
Gait Disturbance	48 (.27%)
Circulatory Collapse	47 (.26%)
Muscular Weakness	47 (.26%)
Pulmonary Oedema	47 (.26%)
Restlessness	47 (.26%)
Unresponsive To Stimuli	47 (.26%)
Apnoea	46 (.26%)
Diplopia	45 (.25%)
Product Quality Issue	45 (.25%)
Pulse Absent	45 (.25%)
Sinus Tachycardia	45 (.25%)
Ventricular Extrasystoles	45 (.25%)
Chondrolysis	44 (.25%)
Condition Aggravated	44 (.25%)
Fall	43 (.24%)
Mydriasis	43 (.24%)
Accidental Overdose	42 (.23%)
Arthralgia	42 (.23%)
Hypoxia	42 (.23%)
Speech Disorder	42 (.23%)
Atrial Fibrillation	41 (.23%)
Dysarthria	40 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Lidocaine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lidocaine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Lidocaine

What are the most common Lidocaine adverse events reported to the FDA?

Neurological	1443 (8.06%)
Cardiac Arrhythmias	1106 (6.18%)
Medication Errors	709 (3.96%)
Cardiac And Vascular Investigations	684 (3.82%)
Respiratory	657 (3.67%)
Epidermal And Dermal Conditions	579 (3.23%)
Procedural And Device Related Injur...	577 (3.22%)
Allergic Conditions	491 (2.74%)
Seizures	438 (2.45%)
Therapeutic And Nontherapeutic Effe...	406 (2.27%)
Infections - Pathogen Unspecified	396 (2.21%)
	Show More
Decreased And Nonspecific Blood Pre...	346 (1.93%)
Gastrointestinal Signs	338 (1.89%)
Chemical Injury And Poisoning	299 (1.67%)
Injuries	292 (1.63%)
Movement Disorders	283 (1.58%)
Musculoskeletal And Connective Tiss...	261 (1.46%)
Vision	241 (1.35%)
Bacterial Infectious	235 (1.31%)
Muscle	224 (1.25%)
Anxiety Disorders	214 (1.2%)
Administration Site Reactions	194 (1.08%)
Ocular Infections, Irritations And ...	186 (1.04%)
Cardiac Disorder Signs	173 (.97%)
Bronchial Disorders	169 (.94%)
Joint	158 (.88%)
Metabolic, Nutritional And Blood Ga...	158 (.88%)
Coronary Artery	152 (.85%)
Ocular Neuromuscular	151 (.84%)
Angiedema And Urticaria	146 (.82%)
Hematology Investigations	135 (.75%)
Vascular Hypertensive	135 (.75%)
Skin Appendage Conditions	134 (.75%)
Deliria	124 (.69%)
Upper Respiratory Tract Disorders	123 (.69%)
Eye	121 (.68%)
Physical Examination Topics	111 (.62%)
Vascular	111 (.62%)
Headaches	110 (.61%)
Lower Respiratory Tract Disorders	107 (.6%)
Oral Soft Tissue Conditions	101 (.56%)
Therapeutic Procedures And Supporti...	101 (.56%)
Body Temperature Conditions	100 (.56%)
Heart Failures	99 (.55%)
Hematological	93 (.52%)
Fatal Outcomes	91 (.51%)
Psychiatric	87 (.49%)
Product Quality Issues	83 (.46%)
Sleep Disorders	79 (.44%)
Ocular Structural Change, Deposit A...	69 (.39%)
Renal Disorders	68 (.38%)
Hepatobiliary	67 (.37%)
Urinary Tract Signs	65 (.36%)
Neuromuscular	64 (.36%)
Gastrointestinal Motility And Defec...	62 (.35%)
Mental Impairment	59 (.33%)
Bone And Joint Injuries	58 (.32%)
Myocardial	58 (.32%)
Tongue Conditions	57 (.32%)
Neurological, Special Senses And Ps...	56 (.31%)
Tendon, Ligament And Cartilage	56 (.31%)
Lifestyle Issues	55 (.31%)
Bone Disorders	53 (.3%)
Changes In Physical Activity	52 (.29%)
Hepatic And Hepatobiliary	52 (.29%)
Cranial Nerve Disorders	51 (.28%)
Disturbances In Thinking	49 (.27%)
Peripheral Neuropathies	49 (.27%)
Retina, Choroid And Vitreous Hemorr...	49 (.27%)
Spinal Cord And Nerve Root	49 (.27%)
Head And Neck Therapeutic Procedure...	48 (.27%)
Electrolyte And Fluid Balance Condi...	47 (.26%)
Vascular Hemorrhagic	45 (.25%)
Obstetric And Gynecological Therape...	44 (.25%)
Anterior Eye Structural Change, Dep...	42 (.23%)
Arteriosclerosis, Stenosis, Vascula...	41 (.23%)
Toxicology And Therapeutic Drug Mon...	39 (.22%)
Mood Disorders	38 (.21%)
Water, Electrolyte And Mineral	38 (.21%)
Acid-base	36 (.2%)
Central Nervous System Vascular	36 (.2%)
Dental And Gingival Conditions	36 (.2%)
Depressed Mood Disorders	36 (.2%)
Immunology And Allergy	35 (.2%)
Enzyme	34 (.19%)
Suicidal And Self-injurious Behavio...	34 (.19%)
Hearing	33 (.18%)
Appetite And General Nutritional	32 (.18%)
Encephalopathies	32 (.18%)
Glucose Metabolism Disorders	32 (.18%)
Tissue	32 (.18%)
White Blood Cell	31 (.17%)
Bone And Joint Therapeutic Procedur...	30 (.17%)
Inner Ear And Viiith Cranial Nerve	27 (.15%)
Skin Vascular Abnormalities	26 (.15%)
Viral Infectious	26 (.15%)
Vulvovaginal Disorders	26 (.15%)
Hepatobiliary Therapeutic Procedure...	23 (.13%)
Communication Disorders	22 (.12%)
Anemias Nonhemolytic And Marrow Dep...	21 (.12%)
Gastrointestinal Conditions	21 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Lidocaine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lidocaine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.